A Genome-engineered Bioartificial Implant for Autoregulated Anti-Cytokine Drug Delivery by 최윤락
1	
A Genome-engineered Bioartificial Implant for Autoregulated Anti-Cytokine Drug Delivery 
 
Yun-Rak Choi1,2,3,4,†, Kelsey H. Collins1,2,3,†, Luke E. Springer5, Lara Pferdehirt1,2,3,6, Alison K. Ross1,2,3,6,  
Chia-Lung Wu1,2,3, Franklin T. Moutos7, Natalia S. Harasymowicz1,2,3, Jonathan M. Brunger8,  
Christine T.N. Pham5, *Farshid Guilak1,2,3,6,7 
 
 
1Department of Orthopaedic Surgery, Washington University in St. Louis, MO, USA 
2Shriners Hospitals for Children – St. Louis, MO, USA 
3Center of Regenerative Medicine, Washington University in St. Louis, MO, USA 
4Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, South Korea 
5Division of Rheumatology, Department of Medicine, Washington University in St. Louis, MO, USA 
6Department of Biomedical Engineering, Washington University in St. Louis, MO, USA 
7Cytex Therapeutics Inc., Durham NC, USA 
8Department of Cellular and Molecular Pharmacology, University of California, San Francisco, USA 
 
 






Farshid Guilak, Ph.D. 
Center of Regenerative Medicine 
Campus Box 8233, Couch Biomedical Research Bldg., Research Bldg, Room 3121 
Washington University in St. Louis 
St. Louis, MO 63110 
Tel.  314-362-7239 
guilak@wustl.edu 
 
Running head: Self-regulating cells for anti-cytokine therapy	  
 
Keywords:   Regenerative medicine, synthetic biology, cell therapy, stem cell, tissue engineering, 
inflammation, arthritis 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted June 9, 2020. ; https://doi.org/10.1101/535609doi: bioRxiv preprint 
2	
Abstract 
Biologic drug therapies are effective treatments for autoimmune diseases such as rheumatoid arthritis (RA) 
but may cause significant adverse effects, as they are administered continuously at high doses that can 
suppress the immune system. Using CRISPR-Cas9 genome editing, we engineered stem cells containing a 
synthetic gene circuit expressing biologic drugs to antagonize interleukin-1 (IL-1) or tumor necrosis factor 
(TNF) in an autoregulated, feedback-controlled manner in response to activation of the endogenous 
chemokine (C-C) motif ligand 2 (Ccl2) promoter. To test this approach in vivo, cells were tissue-engineered 
into a stable cartilaginous construct and implanted subcutaneously in mice with inflammatory arthritis. 
Bioengineered anti-cytokine implants mitigated arthritis severity as measured by joint pain, structural 
damage, and systemic and local inflammation.  The coupling of synthetic biology with tissue engineering 
promises a range of potential applications for treating chronic diseases using custom-designed cells that 
express therapeutic transgenes in response to dynamically changing biological signals.
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Despite advances in the development of disease-modifying anti-rheumatic biologic drugs, 
approximately 40% of patients with rheumatoid arthritis (RA) fail to respond to treatment1. While the 
severity of RA fluctuates, biologic drugs are administered continuously at high concentrations, predisposing 
patients to significant adverse effects, such as increased risk of infection2. The development of therapeutics 
that can sense and respond to dynamically changing levels of endogenous inflammatory mediators may 
improve efficacy while mitigating the side effects of continuous biologic delivery3-5. Here, we used 
CRISPR-Cas9 genome engineering6,7 to create a self-regulating gene circuit in induced pluripotent stem 
cells (iPSCs).  These cells were designed to produce anti-cytokine biologic drugs in response to 
inflammatory signals such as interleukin-1 (IL-1) or tumor necrosis factor a (TNF-a) by transcribing their 
biologic inhibitors in a feedback-controlled manner3, driven by the promoter of the chemokine (C-C) motif 
ligand 2 (Ccl2) (Fig. 1)8. For delivery in vivo, iPSCs were differentiated into a cartilaginous implant and 
engineered into a cartilaginous implant that maintains the cells in a stable subcutaneous depot, allowing for 
sensing of systemic inflammation as well as free diffusion of the biologic drugs into the circulation. We 
demonstrated that these bioengineered implants provide dynamic, autoregulated delivery of anti-cytokine 
biologic drugs that mitigate structural damage, pain, and inflammation in a murine model of arthritis. 
Using CRISPR-Cas9 genome engineering, iPSCs were edited to insert either the gene for IL-1 
receptor antagonist (Il1rn) or luciferase (Luc) at the Ccl2 locus, creating a self-regulating gene circuit that 
transcribes Il1rn or Luc in response to inflammatory activation of Ccl2 (referred as Ccl2-IL1Ra or Ccl2-
Luc cells)3. We initially examined the therapeutic potential of Ccl2-Luc cells9 by intraperitoneal (IP) 
injection into a murine model of K/BxN serum transfer arthritis (STA)10. When triggered exogenously by 
a single IP injection of TNF-a to simulate an RA “flare”, we observed robust luciferase expression (Suppl. 
Fig. 1a) that recovered after the first 24 h (Suppl. Fig. 1b). In the context of K/BxN STA, Ccl2-IL1Ra cells 
delivered by IP injection did not mitigate clinical scores (p=0.10, Suppl. Fig. 1c), but significantly 
suppressed ankle swelling (13.8% reduction on day 6) and mitigated pain sensitivity (25% reduction in 
untreated animals, no change in IL-1Ra treated animals; Suppl. Fig. 1d-f).  
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Due to the lack of long-term cell engraftment by IP injection (as measured by luciferase expression 
after 24h), as well as the modest mitigation of disease severity, we used an alternative tissue-engineering 
approach to create a cartilaginous construct to provide stable engraftment. Cells were seeded onto 3D 
woven poly(e-caprolactone) (PCL) scaffolds (Fig. 2a)11 and chondrogenically differentiated12 over 21 days 
into chondrocyte-like cells that produced a proteoglycan-rich matrix (Fig. 2b-d). In culture, the Ccl2-IL1Ra 
bioartificial implants sensed and responded to stimulation with IL-1a by producing IL-1Ra (Fig. 2e) in a 
feedback-controlled manner (Fig. 2f,g). A second set of cells were similarly engineered to produce soluble 
TNF receptor 1 (sTNFR1), and implants created from Ccl2-sTNFR1 cells behaved similarly in vitro (Suppl. 
Fig. 2). The cell-secreted anti-cytokine biologics suppressed the response to IL-1a or TNF-a, reducing 
mRNA levels for proinflammatory mediators Il6 and Ccl2, and for matrix metalloproteinases, Mmp9 and 
Mmp13 (Fig. 2h-k, Suppl. Fig. 2), as compared to the control Ccl2-Luc construct.  
These bioartificial constructs were implanted subcutaneously onto the dorsal aspect of K/BxN 
transgenic F1 mice, which develop spontaneous arthritis, as well as mice with K/BxN STA10. Ccl2-Luc 
constructs exhibited high luminescence relative to background levels, indicating responsiveness of the 
constructs in vivo, as well as cell survival in a chronic inflammatory environment up to 5 weeks after 
implantation in F1 K/BxN mice (Fig. 2l,m). Ccl2-Luc constructs implanted in the K/BxN STA model 
exhibited similar luminescence signals for 7 days when they were implanted subcutaneously near the knees 
or on the back (Fig. 2n). Explanted Ccl2-Luc constructs from F1 K/BxN mice at 5 weeks also confirmed 
high cell viability via live/dead staining by confocal microscopy (Fig. 2o).   
Chondrocyte-like cells in a cartilage matrix exhibit minimal migration and require no vasculature 
for long-term survival, relying on diffusion for nutrient transport13-16. To determine the ability of this self-
regulating implant to mitigate RA disease severity, constructs were implanted on the dorsal aspect of 
C57BL/6 mice and allowed to recover for 7 days followed by intravenous K/BxN serum administration on 
day 0 (Fig. 3a). Animals receiving Ccl2-IL1Ra implants demonstrated significant improvements in RA 
severity, including 40% reductions in both clinical scores and ankle thickness, compared to control animals 
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that received Ccl2-Luc constructs or no implant (Fig. 3b,c). Histologic analysis showed that animals with 
Ccl2-IL1Ra implants demonstrated significantly lower inflammation scores and had reduced cartilage 
degradation and proteoglycan loss (Fig. 3 d-f) when compared to animals with Ccl2-Luc implants. Mice 
receiving Ccl2-IL1Ra constructs also exhibited significantly higher serum levels of IL-1Ra when compared 
to controls (Fig. 3g,h). Serum IL-1Ra concentrations correlated with clinical scores and ankle thickness 
(Fig. 3i,j). The reduction in disease severity in mice with Ccl2-IL1Ra constructs was accompanied by a 
significant decrease in mechanical pain sensitivity as measured by algometry and Electronic Von Frey pain 
tests, whereas the control groups exhibited increased pain sensitivity (reduced pain thresholds) (Fig. 3k,l). 
The pain threshold of each animal also significantly correlated with serum levels of IL-1Ra (Fig. 3m,n). 
Neither Ccl2-sTNFR1 (Suppl. Fig. 3) nor reducing the dose of Ccl2-IL1Ra constructs by half (Suppl. Fig. 
4) significantly mitigated structural damage from K/BxN STA, although both approaches significantly 
mitigated an increase in pain sensitivity (Suppl. Fig. 3, 4).  These data corroborate previous reports that 
TNF-α and IL-1α signaling are both directly and indirectly associated with the onset of pain in K/BxN 
STA17.   
Microcomputed tomography (microCT) of bone structure showed that mice receiving Ccl2-IL1Ra 
implants had minimal or no bone erosion on day 7 following K/BxN serum transfer, whereas mice with 
Ccl2-Luc implants or no implant exhibited highly erosive disease as demonstrated by a higher ratio of bone 
surface to bone volume (BS/BV) and a lower ratio of bone volume per total volume (BV/TV) (Fig. 4a-c). 
Histologic analysis was also concordant with the microCT observations for bone erosions (Fig. 3d). Ccl2-
IL1Ra implants also showed protective effects on bone mineral density (BMD) (Fig. 4d). Quantitative 
measures of bony erosions (BS/BV) were negatively correlated with serum levels of IL-1Ra (Fig. 4e). Bony 
erosions are frequently observed in RA18 and are associated with disease severity and poor functional 
outcome. However, most biologics currently clinically available rarely inhibit both bone erosions and 
inflammation18. The ability to mitigate both inflammation and structural damage using this approach 
suggests that inhibition of IL-1 signaling in an autoregulated manner may provide added therapeutic 
advantage in the prevention of bone loss during inflammatory arthritis.	
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Mice receiving Ccl2-IL1Ra implants showed significant reductions in their inflammatory cytokine 
profiles as compared to control animals. Using a multiplexed cytokine assay, we observed significant 
reductions of serum levels for IFN-γ and IL-6, and an increase in serum levels for IL-10 in treated animals 
(Fig. 4f-h). In the paw lysate of treated animals, we observed significant reductions in levels for IL-1α, IL-
6, MCP-1, KC, and TNF-a in comparison to control animals (Fig. 4i-m). There was a trend toward 
significance in the total level of IL-1 (IL-1α + IL-1β) in animals that received Ccl2-IL1Ra implants 
compared to controls (p=0.07, Fig. 4n).  
In summary, we developed a genome-engineered implantable drug delivery system that can 
automatically sense and respond to inflammatory cytokines to produce therapeutic levels of anti-cytokine 
biologics in an auto-regulated manner. By engineering iPSCs to form a cartilaginous matrix, the implants 
exhibited long-term viability and function in vivo, with the ability to serve as a continuous source for 
biologic drugs. This platform represents a clinically-relevant and translational delivery strategy that may 
be applicable to a wide variety of diseases for long-term therapeutic control. While protein-based drug 
delivery, including enzyme-activated systems, have been successful in a number of applications19-22, such 
approaches are generally based on biodegradable materials and cannot easily supply continuously biologic 
molecules for long-term delivery, unlike the rapid dynamic stimulus-response functions that living cells 
can provide. In previous studies, “designer” or “smart” cell approaches have been used to develop cell 
therapies for metabolic diseases such as diabetes, but have been based on transient transfection or viral gene 
delivery, resulting in unpredictable gene insertion sites or copy numbers5. This study is among the first to 
demonstrate use of CRISPR-Cas9 gene editing for precise control of the stimulus-response locus in vivo3, 
as well as the potential for tunability and genome editing of cytokine receptors for treating model systems 
of an inflammatory condition23,24.  Applying tissue engineering in combination with synthetic biology25 to 
develop artificial gene circuits that can sense and respond dynamically to disease markers may provide new 
opportunities for developing safe and effective therapies for chronic autoimmune diseases such as RA26. 
  
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted June 9, 2020. ; https://doi.org/10.1101/535609doi: bioRxiv preprint 
7	
Methods 
Cell Culture and In Vitro Assays 
Murine induced pluripotent stem cells (iPSCs) were engineered to incorporate a synthetic gene circuit to 
drive the expression of either Il1rn or firefly luciferase (Luc) via the Ccl2 locus3. These iPSCs were 
predifferentiated in micromass with BMP-412, seeded onto 3D woven poly(ε-caprolactone) (PCL) scaffolds 
(1e6 cells/scaffold), and cultured for 21 days in serum-free chondrogenic medium containing Dulbecco’s 
Modified Eagle Medium - High Glucose (DMEM-HG), non-essential amino acids, 2-mercaptoethanol, 
ITS+ premix (BD), penicillin-streptomycin (Gibco), 50 µg/mL L-ascorbic acid 2-phosphate, 40 µg/mL L-
proline, 10 ng/mL transforming growth factor beta 3 (TGF-b3, R&D Systems) and 100nM 
dexamethasone12,27 to make implantable cartilage constructs11. Gene expression changes in response to 
inflammatory cytokines (1 ng/mL IL-1α or 20 ng/ml TNF-a) were measured via qPCR (primers available 
in Supplementary Methods), and protein levels of secreted murine IL-1Ra were measured via ELISA 
(Duoset, R&D Systems).  
nanoCT Imaging of Bioartificial Implants 
Implants were fixed overnight in 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer 
with 2 mM CaCl2. Secondary fixation was performed using 1% OsO4 in 0.1 cacodylate buffer for 1 hour 
at room temperature. Excess fixative was washed using deionized water, and the samples were incubated 
in Lugol’s iodine for 72 hours at room temperature to further enhance contrast. Samples were embedded in 
2% agarose and imaged on a Zeiss Xradia Versa 540 X-ray microscope using a 0.4x flat panel detector. 
Images were reconstructed and presented as shaded volume renderings. 
In Vivo Luciferase Assays  
Ccl2-Luc constructs were implanted on the dorsal aspect of F1 K/BxN mice, which spontaneously develop 
chronic arthritis, to allow for longitudinal bioluminescence imaging of luciferase activity of the scaffolds 
in vivo daily for one week, and weekly thereafter over a 5-week period. C57BL/6 mice implanted with 
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Ccl2-Luc scaffold constructs were challenged with K/BxN serum and imaged daily for 7 days 
(Supplementary Methods).  
Cell Viability Assays 
Cell survival and apoptosis were assessed using the Live/DeadÒ Cell Viability/ Cytotoxicity Kit for 
mammalian cells (Invitrogen/Molecular Probes, Carlsbad, California, USA). Live cells were labeled with 
calcein AM and dead cells were labeled with ethidium homodimer-1 bound to DNA. Labeled constructs 
were imaged using confocal microscopy (LSM 880, Zeiss, Thornwood, NY, USA)11.  
K/BxN Model of Inflammatory Arthritis  
Male K/BxN transgenic mice and female B6.I-Ag7 mice were intercrossed to generate F1 that spontaneously 
developed arthritis beginning at about 4 weeks of age and lasting for > 20 weeks10.  To induce STA, 
C57BL/6 male and female mice received either dorsal subcutaneous Ccl2-IL1Ra scaffold implants (n=8 
scaffolds, 8 animals, Experimental group), Ccl2-Luc scaffolds or no treatment (Control groups, n=8-13). 
One week after subcutaneous scaffold implantation, mice were challenged with 150-175µL of K/BxN 
serum delivered by retroorbital injection to induce arthritis10,28,29. Disease activity (clinical score and ankle 
thickness) and pain sensitivity (algometry and Electronic Von Frey) were assessed daily for 1 week. Mice 
were then sacrificed, and serum and hindpaws were collected for analysis. All procedures were approved 
by IACUC at Washington University in St. Louis.  
Histological Analysis 
Paws were harvested on day 7 after serum transfer, fixed in 10% neutral buffered formalin for 48 h and 
stored in 70% ethanol, before decalcification in EDTA solution and processing for paraffin embedding. 
Sections (5 µm) were stained with Hematoxylin and Eosin (H&E) or toluidine blue. Inflammatory cells 
infiltrating the synovial lining and the joint cavity were enumerated in 8–10 random fields per section using 
H&E images acquired at 400x magnification. Proteoglycan loss in the cartilage was scored on toluidine 
blue-stained sections on a scale from 0–3, ranging from fully stained cartilage (score = 0) to fully destained 
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cartilage (score = 3) as previously described30. Scoring was performed by an observer blinded to the 
treatment. 
Quantitation of IL-1Ra and Proinflammatory Mediators 
Levels of IL-1Ra in serum and paws were assessed by ELISA (Quantikine-IL1Ra, R&D Systems).  Levels 
of paw and serum inflammatory mediators were evaluated using Luminex® (Mouse High Sensitivity T-
cell discovery array 18-Plex, Eve Technologies, Calgary, AB, Canada).  
MicroCT Analysis of Bone Erosion 
To measure bone morphological changes, intact hind paws were scanned by microcomputed tomography 
(microCT, SkyScan 1176, Bruker) with a 9 µm isotropic voxel resolution at 50 kV, 500 µA, 980 ms 
integration time, 3 frame averaging, and 0.5 mm aluminum filter to reduce the effects of beam hardening. 
Images were reconstructed using NRecon software (with 20% beam hardening correction and 15 ring 
artifact correction). Hydroxyapatite calibration phantoms were used to calibrate bone density values 
(g/cm3). Parameters reported are: bone surface to bone volume (BS/BV), bone fraction (bone volume/total 
volume; BV/TV), and bone mineral density (BMD; g/cm3). 
Statistical Analysis 
Sample size was determined based on a mean of 10 ± 2 for KRN control animals and 6 for IL-1Ra treated 
animals. Based on an alpha of 0.05 and 80% statistical power (1-β) a priori a sample size of 4 
animals/treatment group was needed to observe this effect. Outcomes were evaluated by two-way Student’s 
t-test, one-way Mann-Whitney U test or one-, two-, three-way repeated measures, or three-way ANOVA 
with Tukey’s post hoc test or Sidak Correction to assess differences between groups, treatments, scaffold 
types, time, or a combination of those factors. Pearson or Spearman correlations were calculated between 
serum levels of IL-1Ra and outcomes (p ≤ 0.05).  Investigators were not blinded to the clinical score or 
ankle thickness measurements. All other assessments and analyses were performed blinded. 
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Fig. 1. Scaffold-mediated Delivery of Genome-engineered Anti-Cytokine Cells. a. CRISPR-Cas9 
genome editing was used to engineer stem cells containing a synthetic gene circuit that expresses the 
interleukin-1 receptor antagonist (IL-1Ra), an inhibitor of IL-1, in response to activation of the chemokine 
(C-C) motif ligand 2 (Ccl2) promoter. b. Cells were engineered to form stable cartilaginous constructs on 
3D woven scaffolds in chondrogenic media. Constructs were tested in vitro to assess on-off dynamics in 
response to changing levels of IL-1. c. To test their efficacy, these anti-cytokine constructs were implanted 
subcutaneously in K/BxN model of rheumatoid arthritis.  
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Fig. 2. Tissue-engineered Bioartificial Implants Sense and Respond to Inflammation in a Feedback-
controlled Manner. a-d. Genome-engineered stem cells on porous 3D woven scaffolds (a, electron 
microscopy) were differentiated into chondrocyte-like cells that infiltrated the scaffold and filled the 
scaffold pores with cartilaginous matrix as shown by b. confocal microscopy; c. nanoCT; d. Safranin O 
staining. e. Ccl2-IL1Ra constructs produced IL-1Ra in response to IL-1a and f. decreased IL-1Ra 
production rapidly after IL-1a withdrawal. g. This response was repeatable over multiple cycles of iterative 
stimulation (n = 5 per group). h-k. Ccl2-IL-1Ra constructs (n = 6) mitigated mRNA levels for pro-
inflammatory mediators as compared to Ccl2-Luc constructs (n = 5). l-o. When implanted in K/BxN model 
of rheumatoid arthritis, Ccl2-Luc implants expressed consistent luciferase (m,n) and demonstrated high 
cell viability (o) upon explantation for confocal microscopy (n ³ 3 per group). All values represent mean ± 
SEM. In e, three-way repeated measured ANOVA, in g, Students’ t-test: *** indicates p < 0.001. In h-k 
and n, two-way ANOVA: different letters indicate p < 0.001 by Tukey’s post-hoc test. 
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Fig. 3. Ccl2-IL1Ra Bioartificial Implants Mitigate Disease Severity, Inflammation, and Pain in Mice 
with K/BxN Serum Transfer Arthritis.  a-c, Ccl2-IL1Ra implants mitigated disease severity as measure 
by clinical scores and ankle thickness, in contrast to control groups (n = 20, 12, 8, respectively). d-f. At 
sacrifice, these implants reduced inflammation (e, n = 8, 9, left to right) and maintained cartilage integrity 
(f. n = 7 per group). g-j. IL-1Ra levels and ratio of IL-1:IL-1Ra in serum were increased in mice with Ccl2-
IL1Ra implants compared to all other groups and IL-1Ra concentration in serum had negative relations 
with clinical scores, ankle thickness (g. n = 10, 6, 12, 8, left to right; h. n= 10 per group). k-n. For pain 
measurements, mice receiving Ccl2-IL1Ra implants maintained their pain thresholds, indicated by 
algometry and Electronic Von Frey pain tests in contrast to all other groups and significantly related with 
IL-1Ra concentration in serum (n = 20, 12, 8, respectively). All values represent mean ± SEM. In b, c, k, 
and l, two-way repeated measures ANOVA; in e and f, one-sided Mann-Whitney U test; in g, one-way 
ANOVA; in h, Students’ t-test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Fig. 4. Ccl2-IL1Ra Bioartificial Implants Prevent Bone Damage and Mitigate Endogenous 
Inflammation in Mice with K/BxN Serum Transfer Arthritis. a-e. Mice treated with Ccl2-IL1Ra 
implants demonstrated reduced bone damage by microCT as quantified by b. the ratio of bone surface to 
bone volume (BS/BV); c. bone volume per total volume (BV/TV); d. bone mineral density (BMD); (n = 
10, 7, 12, 7, left to right). e. Significant relationships were observed between BS/BV and serum levels for 
IL-1Ra. f-n. Mice receiving Ccl2-IL1Ra implants also showed less systemic (f-h) and local inflammation 
(i-n) as compared to mice with Ccl2-Luc implants or no implants (n = 10 per group). All values represent 
the mean fold change in expression ± SEM. In b-d, one-way ANOVA; in f-n, Students’ t-test; *P < 0.05, 
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Suppl. Fig. 1 
To assess an alternative cell delivery approach, Ccl2-Luc cells were delivered by IP injection in 200µL of 
sterile PBS to K/BxN STA mice. a. The injected cells demonstrated rapid luciferase expression (within 1h) 
in response to supraphysiological levels of pro-inflammatory cytokines (a, left TNF-a challenge with Ccl2-
Luc cells; right no TNF-a challenge with Ccl2-Luc cells).  b. Luciferase expression decreased over 6 days. 
c. With K/BxN serum transfer after IP injection of Ccl2-IL1Ra cells, significant mitigation of clinical scores 
was not observed (p=0.10), but d. did result in significant mitigation of ankle thickness with TNF-a 
challenge. IP injected Ccl2-IL1Ra cells also mitigated pain measured by e. algometry and f. Electronic Von 
Frey respectively in K/BxN STA mice, but to a lesser degree than when compared with the tissue-
engineered Ccl2-IL1Ra cartilage scaffold constructs (e, f). All values represent mean ± SEM. *p < 0.05. 
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Suppl. Fig. 2 
Ccl2-sTNFR1 anti-cytokine cartilaginous constructs mitigated mRNA levels for pro-inflammatory 
mediators a. Il6, b. Ccl2, c. Mmp13, and d. Mmp9 when challenged with 20 ng/mL TNF-a. e. Ccl2-sTNFR1 
constructs produced sTNFR1 in response to cytokine challenge. f. This response was repeatable over 
multiple cycles of stimulation. g. The levels of sTNFR1 were reduced to baseline levels after cytokine 
withdrawal. All values represent mean ± SEM. * and different letters indicate p<0.05. 
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Suppl. Fig. 3. 
K/BxN serum transfer arthritis mice implanted with Ccl2-IL1Ra constructs demonstrated a. reduced clinical 
scores and b. ankle thickness when compared to mice receiving Ccl2-Luc constructs, Ccl2-sTNFR1 
constructs, or mice receiving no implants.  c. Mice with Ccl2-IL1Ra implants maintained their pain 
thresholds, indicated by algometry d. Both Ccl2-sTNFR1 and Ccl2-IL1Ra groups maintained pain 
thresholds using the Electronic Von Frey pain test. e. At sacrifice, significant increases in sTNFR1 
concentration in serum from mice receiving Ccl2-sTNFR1 implants was observed compared to mice with 
no implants. f. No significant correlation was observed between sTNFR1 levels and the clinical score, but 
sTNFR1 concentration in serum were correlated with g. algometry and h. Von Frey pain thresholds. All 
values represent mean ± SEM. *p < 0.05. 
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Suppl. Fig. 4 
A dose-response was observed in genome-engineered constructs depending on the number of cells 
implanted (Ccl2-Luc, Ccl2-IL1Ra 8 implants [8e6 cells total, full dose] or Ccl2-IL1Ra 4 implants [4e6 
total, half dose]) were implanted subcutaneously in mice with K/BxN serum transfer arthritis. a. Mice 
receiving Ccl2-IL1Ra implants demonstrated reduced clinical scores, and b. reduced ankle thickness as 
compared to mice receiving Ccl2-Luc implants, and both mice receiving half dose and no implants.  c. Both 
Ccl2-IL1Ra treated groups maintained their pain thresholds, indicated by algometry.  d. Approximately 
half the concentration of IL-1Ra was observed in the serum of the Ccl2-IL1Ra half dose group on average 
compared to Ccl2-IL1Ra full dose. Only the Ccl2-IL1Ra full dose group demonstrated significant increases 
in circulating IL-1Ra compared to mice with no implants. All values represent mean ± SEM. *p < 0.05. 
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In Vivo Luciferase Assays  
In vivo bioluminescence imaging was performed on the days indicated on an IVIS Lumina (PerkinElmer, 
Waltham, MA, USA; Living Image 4.2, 1 min exposure, bin 8, FOV 12.5cm, f/stop 1, open filter).  Hair 
was removed from the area prior to imaging. Mice were injected intraperitoneally with D-luciferin (150 
mg/kg in PBS; Gold Biotechnology, St. Louis, MO, USA) and imaged using isoflurane anesthesia (2% 
vaporized in O2).  Total photon flux (photons/sec) was measured from fixed regions of interest (ROIs) over 
the lower backs of the mice where the scaffolds were located using Living Image 2.6.   
K/BxN Serum Transfer Experiments 
The clinical score was assessed on a scale of 0–3 (0=no swelling or erythema, 1=slight swelling or 
erythema, 2=moderate erythema and swelling in multiple digits or entire paw, 3=pronounced erythema and 
swelling of entire paw; maximum total score of 12)30. The change from baseline in ankle thickness was 
determined daily by dial calipers, and an average change in the ankle thickness was determined for each 
mouse from the two hind paw measurements.  
Animals were acclimatized to the behavioral testing room prior to assessment. Algometry was performed 
using a pressure-based analgesimeter (SMALGO, Bioseb, Vitrolles, France) by applying a progressive 
force over the ankle joint, and the stimulation was increased until a reaction (shudder or vocalization) from 
the animal was obtained. The maximum force was then automatically recorded and analyzed. 
For Electronic Von Frey paw tests, mice were placed in acrylic cages (12 x 10 x 17 cm high) with a wire 
grid floor 15-30 min before testing in a quiet room. During this adaptation period, the hind paws were poked 
2-3 times. Before hind paw stimulation, the animals were quiet, without exploratory movements or 
defecation, and not resting on their paws. In these experiments, we used a pressure-meter which consisted 
of a hand-held force transducer fitted with a 0.5 mm2 polypropylene tip (electronic von Frey 
anesthesiometer, IITC Inc., Life Science Instruments, Woodland Hills, CA, USA). Then, a tip was applied 
against the central edge of the animal hind paw and the intensity of the stimulus was automatically recorded 
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when the paw was withdrawn. The stimulation of the paw was repeated until the animal presented two 
similar measurements. 
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